Noel Warfel was staring at a paradox: a cancer drug that worked exactly as designed, yet failed in practice. At MUSC Hollings Cancer Center in Charleston, his team had been studying PIM1, a protein that turbocharges prostate cancer growth and treatment resistance. For years, researchers had developed inhibitors to block PIM1’s kinase activity—its chemical engine—and yet, in patients with solid tumors, these drugs fizzled. The reason, Warfel and his colleagues discovered, wasn’t failure—it was adaptation. Cancer cells weren’t just surviving the treatment; they were using it to their advantage.
Their breakthrough, published in Cancer Letters, reveals a hidden survival pathway that explains why traditional PIM1 inhibitors fall short. When these drugs block PIM1’s signaling, they inadvertently cause cancer cells to accumulate more of the protein. And even when inactive, PIM1 isn’t harmless—it’s still hard at work keeping tumors alive. The team found that excess PIM1 binds to another protein, HMGB1, normally stationed in the nucleus to manage DNA damage. But when PIM1 drags HMGB1 into the cytoplasm, it flips a switch: HMGB1 activates autophagy, a cellular cleanup process that removes damaged mitochondria. Without these broken powerhouses spewing toxic molecules, cancer cells dodge the oxidative stress meant to kill them.
"We're blocking one survival effect but at the same time increasing another side of the coin," Warfel said. "Just by being present in the cell, PIM1 can promote resistance." This discovery reframes the challenge—not inhibition, but elimination. Enter PIMTAC, a PROTAC (proteolysis-targeting chimera) developed in Warfel’s lab. Unlike traditional inhibitors, PIMTAC doesn’t just silence PIM1—it marks it for destruction. In lab studies and mouse models, removing PIM1 entirely prevented the HMGB1 hijack, increased oxidative stress, and led to significantly more cancer cell death. The degrader didn’t just stop the engine; it dismantled the entire machine.
The implications are profound. Prostate cancer is the second leading cause of cancer death in American men, and resistance to therapy remains a major hurdle. By exposing this PIM1-HMGB1 axis, Warfel’s work offers a roadmap for smarter drug design—one that doesn’t just block proteins but removes them. PIMTAC is still experimental, but it represents a shift from inhibition to eradication. As research moves toward clinical testing, the hope is that this new strategy won’t just delay progression, but disrupt it. For a disease that adapts with ruthless efficiency, the best countermove may be to leave nothing behind.